OctoPlus opens new GMP facility in the Netherlands
OctoPlus has begun pharmaceutical production at its new manufacturing facility in Leiden. The site has received a licence from the Dutch authorities to manufacture pharmaceutical products according to GMP guidelines and the first production has taken place successfully.
OctoPlus has begun pharmaceutical production at its new manufacturing facility in Leiden. The site has received a licence from the Dutch authorities to manufacture pharmaceutical products according to GMP guidelines and the first production has taken place successfully.
The expansion of OctoPlus" headquarters started in November 2006. The new building comprises offices, laboratories and the GMP manufacturing plant, which produces final drug product.
OctoPlus has more than doubled its manufacturing capacity with the expansion and can now produce clinical scale Phase I, II, III and even small-scale commercial supplies of injectable pharmaceutical products and other complex formulations.
Simon Sturge, ceo of OctoPlus, said: "We are very proud to report that the expansion of the production facility in our headquarters in Leiden has obtained official approval from the Dutch authorities and we have now started producing pharmaceutical products as a fully licensed facility."